Smartphones Spot Ocular Malignancies

• July 2, 2026

Correction: Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells

• by Helena de Castro e Gloria, Laura Jesuíno Nogueira, Patrícia Bencke Grudzinski, Paola Victória da Costa Ghignatti, Temenouga Nikolova Guecheva, Natalia Motta Leguisamo, Jenifer Saffi

• July 1, 2026

A novel bimanual endoluminal robotic platform compatible with standard gastroscopes for endoscopic submucosal dissection: preclinical feasibility and ergonomic evaluation

• by Yung Lee, Ji Seok Park, Stephen Firkins, Sera Satoi, Vikash Fnu, Kyungran Justina Cho, Amit Bhatt

• July 1, 2026

ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101

A-DREAM/Alliance A032101 study presented by Dana-Farber Cancer Institute's Dr. Atish Choudhury shows 41% of favorable responders to testosterone suppression plus androgen receptor pathway inhibitor remaining treatment-free with testosterone recovery at 18 months after treatment interruption.

• July 1, 2026

• 1 min